RALEIGH, N.C.--(BUSINESS WIRE)--Jan. 4, 2006--Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced the successful completion and outcome of its first Phase III study to evaluate the efficacy and safety of XIFAXAN(R) (rifaximin) tablets 200 mg for the prevention of travelers' diarrhea (TD).
